Rebecca J. Peterson
Investor Relations Contact at EXICURE, INC.
Profile
Rebecca J.
Peterson is currently working as a Member at National Investor Relations Institute and as Vice President & Head-Corporate Communications at Exicure, Inc. She previously worked as Senior Vice President-Corporate Communications at Alkermes, Inc. and Alkermes Plc, Manager-Corporate Communications at Millennium Pharmaceuticals, Inc., and Head-Corporate Communications at Dicerna Pharmaceuticals, Inc. She has graduate degrees from Emerson College and Tufts University School of Medicine and an undergraduate degree from the University of Massachusetts.
Rebecca J. Peterson active positions
| Companies | Position | Start |
|---|---|---|
| EXICURE, INC. | Investor Relations Contact | - |
National Investor Relations Institute
 National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Corporate Officer/Principal | 1997-12-31 |
Former positions of Rebecca J. Peterson
| Companies | Position | End |
|---|---|---|
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Investor Relations Contact | - |
| ALKERMES PLC | Public Communications Contact | 2014-12-31 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Public Communications Contact | 1999-12-31 |
| DICERNA PHARMACEUTICALS, INC. | Public Communications Contact | - |
Training of Rebecca J. Peterson
| University of Massachusetts | Undergraduate Degree |
| Tufts University School of Medicine | Graduate Degree |
| Emerson College | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALKERMES PLC | Health Technology |
| EXICURE, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
National Investor Relations Institute
National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Commercial Services |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Rebecca J. Peterson
